FDA Investigator Daniel R Solis
Daniel R Solis has conducted inspections on 5 sites in 1 countries as of 15 Feb 2023. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
5
Last Inspection Date:
15 Feb 2023
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America
FDA Investigators that have inspected at least one site in common with Daniel R Solis:
Ashar P Parikh,
Bruce W Benware,
Bryan A Galvez,
Carla J Lundi,
Caryn M Everly,
Caryn M Mcnab,
Cathleen A Carr Sharpe,
Chelsea N Sealey,
Christopher R Czajka,
David Serrano,
Davis,
Donna Ltartaglino Besone,
Francisco,
Garciam,
Greg K Keshishyan,
Henry E Carrillo,
Jane S Wernberg,
Jennifer Crumb,
Jennifer M Gogley,
Jinnie Kokiatkulkij,
Jocelyn E Massey,
Jocelyn E Sparks,
Joey V Quitania,
John A Gonzalez,
Joseph S Fanelli,
Kari M Johansen,
Katherine E Jacobitz,
Kelvin Cheung,
Kelvin X Sanders,
Kham Phommachanh,
Khoa Nathanv Tran,
Lilly O Barton,
Linda Thai,
Lisa Shin,
Louis B Cencetti,
Lourdes M Countee,
Marco S Esteves,
Marcus F Yambot,
Marie Falcone,
Marie T Falcone,
Mark A Tucker,
Mark C Saale,
Matthew J Johnson,
Maxyne T Lam,
Michael D Garcia,
Michael D Kawalek,
Mihaly S Ligmond,
Nianna C Burns,
Nicholas L Hunt,
Phal K Chhun,
Phillip L Toy,
Raymond T Oji,
Robert C Coleman,
Sara Jdent Acosta,
Sean P Desbrow,
Sonia R Peterson,
Sonya L Karsik, RAC,
Stephanie A Slater, MS,
Sudipan Karmakar,
Taichun Qin, PhD,
Tamala P Magee,
Terri L Dodds,
Timothy P Lafave,
Uttaniti Limchumroon (Tom),
Virgilio F Pacio, CSO,
William J Leonard,
Yumi J Hiramine,
Yvette Mlacour Davis
Daniel R Solis's Documents
Publish Date | Document Type | Title |
---|---|---|
February, 2000 | EIR | International Medication Systems, Ltd. - EIR, 2000-02-09 |
February, 2000 | FDA 483 | International Medication Systems, Ltd. - Form 483, 2000-02-09 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more